Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction

T. Pertseva, K. Gashynova, O. Gurzhiy, N. Klimenko (Dnipropetrovs‘k, Ukraine)

Source: Annual Congress 2009 - Drug effects in COPD
Session: Drug effects in COPD
Session type: Thematic Poster Session
Number: 2014
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Gurzhiy, N. Klimenko (Dnipropetrovs‘k, Ukraine). Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction. Eur Respir J 2009; 34: Suppl. 53, 2014

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles
Year: 2010


The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014


Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB)
Source: Eur Respir J 2006; 28: Suppl. 50, 395s
Year: 2006

Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015


Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 288s
Year: 2003

Lower respiratory tract infection (LRTI): are there differences of microbial spectrum in stable phase (SP) of COPD and during acute exacerbation (AE)?
Source: Annual Congress 2009 - COPD: exacerbation and clinical problems
Year: 2009


Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015


Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection?
Source: Eur Respir J 2001; 18: Suppl. 33, 172s
Year: 2001

Does tolerance of neuro-muscular electrical stimulation (NMES) relate to gender in patients with an acute exacerbation (AE) of chronic obstructive pulmonary disease (COPD)?
Source: Annual Congress 2012 - Physiotherapy and rehabilitative interventions applied to different populations with respiratory impairment
Year: 2012


Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013

Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD
Source: International Congress 2015 – Different data in COPD
Year: 2015

Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples
Source: Eur Respir J 2005; 26: Suppl. 49, 595s
Year: 2005

Patient’s knowledge about risk factors for acute exacerbation( AE ) of chronic obstructive pulmonary disease( COPD )
Source: Eur Respir J 2004; 24: Suppl. 48, 514s
Year: 2004

COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016

Comparative evaluation of different methods of correction of mucociliary transport (MCT) insufficiency in patients with chronic bronchitis (CB)
Source: Annual Congress 2006 - Implications of progressive airway obstruction
Year: 2006

Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 564s
Year: 2002

Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 557s
Year: 2007

COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012

Cognitive decline following an acute exacerbation of COPD (AECOPD)
Source: Virtual Congress 2020 – Investigations of COPD
Year: 2020


Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003